Background and objective: According to several studies, tuberculosis (TB) may be involved in the pathogenesis of cardiovascular disease. However, the relationship between TB and peripheral arterial disease (PAD) has not been studied. The aim of this study was to investigate whether patients with TB exhibit an increased risk of developing PAD. Methods: The data assessed in this national population-based cohort study were obtained from the Taiwan National Health Insurance Database from 2000 to 2010. Patients with newly diagnosed TB were selected using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The non-TB cohort was randomly frequency-matched to the TB cohort at a ratio of 2:1 according to age, sex and index year. Cox's proportional hazards regression models were used to analyse the risk of PAD. Results: We enrolled 14 350 patients with TB and 28 700 controls in this study. The risk of PAD was 3.93-fold higher in the patients with TB than in the non-TB controls after adjusting for age, sex, co-morbidities and socio-economic status. Based on the subgroup analysis, the TB cohort exhibited an increased risk of developing PAD compared with the non-TB cohort, regardless of age, sex, co-morbidities and socio-economic status. Patients with TB had a higher risk of developing PAD than healthy control subjects after 1 year of follow-up. Conclusion: Patients with TB have a significantly higher risk of developing PAD than patients without TB. TB should be considered when evaluating a patient's risk of developing PAD.
INTRODUCTION
Tuberculosis (TB) was one of the top 10 causes of death in the world in 2015, and the TB epidemic has been underestimated in the past few years. 1 According to the World Health Organization, approximately 10.4 million people developed TB and 1.4 million people died from TB worldwide in 2015. 1 In Taiwan, TB is a common disease, with an incidence of 53 patients per 100 000 population, and 626 TB-related deaths occurred in 2012. 2 TB is a chronic inflammatory disease caused by Mycobacterium tuberculosis, which utilizes several methods to survive the intracellular environment and is involved in the production of multiple cytokines. [3] [4] [5] [6] The diseases that predispose individuals to TB infection include human immunodeficiency virus (HIV) infection, diabetes, immune-mediated inflammatory disorders, end-stage renal disease and silicosis, among others. [7] [8] [9] On the other hand, TB primarily results in pulmonary TB, which could lead to conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, restrictive lung diseases, destructive lung diseases and bronchial stenosis, and could cause extrapulmonary TB in the lymph nodes, pleural cavity, bones or joints, genitourinary tract, meninges or peritoneum (infection sites listed in order of proportion). 10 Furthermore, some systemic diseases that seem to be related to TB have been reported, such as acute coronary syndrome, liver cirrhosis, systemic lupus erythematosus and Parkinson's disease. [11] [12] [13] [14] Peripheral arterial disease (PAD) is a disease of the circulatory system that decreases blood flow to peripheral tissues, is primarily caused by atherosclerosis and induces tissue injury. The prevalence of PAD is approximately 12-14% in the general population, and the prevalence increases with age to affect 20% of patients over 75 years. 15 In 2010, PAD affected 202 million people globally, and it currently remains one of the most critical public health issues. 16 Common risk factors for PAD include old age, hypertension, type 2 diabetes, smoking, hypercholesterolaemia and obesity. 17, 18 Some infectious diseases, including pneumonia, chronic bronchitis, chickenpox, shingles and mumps, have also been reported to be independently associated with PAD. 19, 20 Inflammation participates in all stages of atherosclerosis, from initiation and progression to complications, and leads to the development of various circulatory diseases, including PAD. [21] [22] [23] [24] TB infection is an inflammatory process involving interactions between the inflammatory response and suppressive mediators. 25, 26 Furthermore, the role of TB in the development of cardiovascular disease (CVD) epidemics and pathogenesis has been discussed in recent years. 27 However, the relationship between TB and PAD has not been studied. We conducted a longitudinal nationwide population-based cohort study to investigate whether TB increased the risk of PAD.
METHODS

Data source
This study was conducted using data from the Longitudinal Health Insurance Database (LHID), which was derived from Taiwan's National Health Insurance (NHI) programme. This programme has been implemented by the government since 1995 and provides health insurance to approximately 99% of the 23.74 million Taiwanese residents. The identification of diseases in the National Health Insurance Research Database (NHIRD) was conducted according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). For privacy protection, all information obtained from patients was anonymized and could not be identified. All insurance claims were scrutinized by medical reimbursement specialists, and the representativeness of the NHIRD for the entire Taiwanese population has been validated by several studies. 28, 29 This study was approved by the Institutional Review Board of Tri-Service General Hospital.
Study participants
This population-based retrospective cohort study included a TB cohort and a non-TB cohort. The TB cohort comprised patients who were newly diagnosed with TB (ICD-9-CM 010-018) between 1 January 2000 and 31 December 2010 (Table S1 , Supplementary Information). We defined the index date as the date of TB diagnosis. The follow-up period was defined as the time from the index date to the date of PAD diagnosis. The exclusion criteria included a history of TB or PAD before the index date, age < 20 years and missing information (age or sex). The non-TB cohort was randomly selected from the NHIRD using the same exclusion criteria. Two patients from the non-TB cohort were matched with each patient included in the TB cohort according to sex, age and index year.
End point and co-morbidities
The end point of this study was the development of a new diagnosis of PAD (ICD-9-CM 440. (Table S2 , Supplementary Information). The diagnosis of PAD was based on the ICD-9-CM and was determined by relevant specialists according to typical symptoms, laboratory data and imaging of PAD. All patients were followed up from the index date to the diagnosis of PAD, withdrawal from NHI programme, death or 31 December 2010. The comorbidities we used included diabetes mellitus (DM; ICD-9-CM 250), hypertension (ICD-9-CM 401-405), hyperlipidaemia (ICD-9-CM 272), CVD, stroke (ICD-9-CM 430-438), COPD (ICD-9-CM 490-491, 495-496), asthma (ICD-9-CM 493), chronic kidney disease (CKD; ICD-9-CM 585), HIV (ICD-9-CM 042, 043, 044 and V08) infection, hepatitis C virus (HCV; ICD-9-CM 070.41, 070.44, 070.51, 070.54, 070.7 and V02.62) infection, urbanization level and monthly income (insured premium). CVD included ischaemic heart disease (IHD; ICD-9-CM 401-414), heart failure (HF; ICD-9-CM 428) and atrial fibrillation (AF; ICD-9-CM 427.31) to address the collinear nature of these diseases. Because smoking is a common risk factor for PAD that was not identified in the NHIRD, we selected smokingrelated diseases, including IHD, stroke, COPD and asthma for adjustments to minimize the confounding effect of smoking. 30, 31 Patients were considered to have a co-morbidity if they were diagnosed before the index date.
Statistical analysis
We used a chi-square test to determine differences in demographic data and co-morbidities between the TB and non-TB cohorts. Cumulative incidence curves of PAD were estimated for both cohorts using a KaplanMeier analysis, and a log-rank test was used to determine differences between cohorts. The incidence rate ratio of PAD in both cohorts was estimated using a Poisson regression analysis. The adjusted hazard ratio (HR) and 95% CI of PAD development in both cohorts were estimated using univariate and multivariate Cox proportional hazards regression analyses. SAS 9.4 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. A two-tailed P < 0.05 was considered statistically significant.
RESULTS
We enrolled 14 350 patients in the TB cohort and 28 700 patients in the non-TB cohort after frequency matching for sex, age and index year. The distributions of sex and age were similar in both groups. The mean follow-up period was 5.62 (SD = 3.78) years in the TB cohort and 6.01 (SD = 3.85) years in the non-TB cohort. Compared with the non-TB cohort, patients in the TB cohort had a higher prevalence of DM, COPD, HIV and HCV and a lower prevalence of hypertension, hyperlipidaemia, CVD, stroke, CKD and urbanization level ( Table 1 ). The patient selection procedure is depicted in detail in Figure S1 (Supplementary Information).
Patients in the TB cohort had a higher risk of developing PAD than the non-TB cohort according to the Cox regression model (adjusted HR = 3.93, 95% CI = 3.03-4.95) ( Table S3 , Supplementary Information). Patients with DM, CVD, stroke or HIV exhibited a significantly higher risk of developing PAD than patients without these co-morbidities (adjusted HR = 1.77, 95% CI = 1.32-2.22; adjusted HR = 1.79, 95% CI = 1.32-2.18; adjusted HR = 1.39, 95% CI = 1.00-1.94; and adjusted HR = 2.36, 95% CI = 1.01-16.44, respectively). As shown in Figure 1 , patients in the TB cohort had a significantly higher cumulative incidence of PAD than patients in the non-TB cohort during the 11-year follow-up period (log-rank test < 0.001).
The incidence density rates (IR) and adjusted HR of PAD based on TB status stratified by demographic factors and co-morbidities are shown in Table 2 . Patients in the TB cohort had higher IR than patients in the non-TB cohort (5.37 vs 3.73 per 1000 person-years). The IR increased with age in both cohorts (IR in age groups 20-44, 45-69 and ≥70 years = 3.04, 5.49 and 5.69 in the TB cohort and 1.25, 1.67 and 5.08 in the non-TB cohort, respectively). In the co-morbidityspecific analysis, patients in the TB cohort had a significantly higher HR for PAD than patients in the non-TB cohort, regardless of the presence of co-morbidities, with the exception of the subgroups with asthma, CKD, HIV, level 3 urbanization and monthly income ≥35 000 (NT$ (1 US$ = 31.5 NT$ in 2016)).
The TB cohort was divided into pulmonary TB, miliary TB and extrapulmonary TB according to ICD-9-CM codes, and the numbers of patients in these subgroups were 11 954 (83.3%), 229 (1.60%) and 2519 (17.55%), respectively. Table 3 shows the incidence and adjusted HR of PAD for patients with different forms of TB. Patients with pulmonary TB and extrapulmonary TB had a 3.90-and 2.11-fold higher risk of developing PAD than patients in the non-TB cohort. Table 4 shows the incidence and adjusted HR of PAD for these two cohorts according to the follow-up periods. The TB cohort had a 3.45-fold higher risk of developing PAD than the non-TB cohort for a followup duration of 1-5 years (adjusted HR = 3.45, 95% CI = 2.00-4.62). For a follow-up period of longer than 5 years, the TB cohort also had a 2.86-fold higher risk of developing PAD than the non-TB cohort (adjusted HR = 2.86, 95% CI = 1.04-3.98).
DISCUSSION
To the best of our knowledge, this population-based cohort study is the first to investigate the relationship between TB and PAD. In the Cox proportional hazards model, patients with TB had a 3.93-fold higher risk of developing PAD than patients without TB after adjusting for sex, age, socio-economic status and comorbidities that were considered risk factors for PAD.
The development of atherosclerosis is the major aetiology of PAD, and several infectious pathogens have been shown to play a role in the pathogenesis of atherosclerosis, including HCV, Chlamydia pneumoniae and HIV. [32] [33] [34] Based on our study, M. tuberculosis may be another infectious agent that participates in the development of atherosclerosis and, subsequently, PAD. We propose some mechanisms that may underlie the increased risk of PAD in patients with TB. First, chronic inflammation plays a crucial role in the pathogenesis of both TB and atherosclerosis, which feature similar pro-inflammatory cytokines (interleukin-1 (IL-1), IL-2, IL-6, interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α)) and immune cells (monocytes, macrophages, CD4+ T helper 1 (TH1) and TH17 cells). 27 Van Eeden et al. also proposed plausible mechanistic pathways from lung inflammation induced by smoking, air pollution particles or pathogens to atherosclerosis mediated by an inflammatory cytokine storm. 35 Second, an association between increasing titres of mycobacterial heat-shock protein 65 (mHSP65) antibodies and elevated coronary calcification levels was reported in humans. 36 Through the anti-mHSP65 antibody, TB may exert a pathogenic effect on atherosclerosis mediated by molecular mimicry and autoimmunity. 27, 37 Furthermore, a hypercoagulable state induced by increased plasma fibrinogen levels, decreased antithrombin III levels and increased platelet aggregation has been observed in patients with TB. 38 Although patients in the TB and non-TB cohorts had different prevalences of co-morbidities, including DM, hypertension, hyperlipidaemia, CVD, stroke, COPD, CKD, HIV, HCV and urbanization level, on the index day, TB remained an independent risk factor for PAD in the adjusted Cox regression analysis. Moreover, male gender, old age, diabetes, CVD, stroke and HIV were independent risk factors for PAD, consistent with the findings of other studies. 15, 19 Patients in the TB cohort had a higher incidence of PAD than patients in the non-TB cohort in most of the subgroup analyses of sex, age, co-morbidity and socio-economic status.
Miliary TB is an infectious disease caused by haematogenous dissemination of M. tuberculosis to vessels throughout the body, and the effects of atherosclerosisinduced TB may theoretically have a greater influence than pulmonary or extrapulmonary TB. 39, 40 Furthermore, patients with miliary TB and PAD have the same predisposing disease factors, including DM, alcoholism, CKD and HIV infection. [41] [42] [43] [44] Patients in the subgroup with miliary TB had a higher IR and adjusted HR, but this relationship was not statistically significant. Patients with miliary TB may have shown a higher risk of developing PAD than the control group, but this difference did not reach statistical significance because few miliary patients were enrolled in this study.
It is reasonable to suppose that the diagnosis of PAD increased when TB patients sought medical care. However, we analysed the cohorts stratified by follow-up year and found that the adjusted HR of PAD significantly increased during the 1-5 years and >5 years of the follow-up periods, but not during the first year. The slow and chronic process by which atherosclerosis leads to the development of vascular disease involves intimal thickening followed by fibrocalcific plaque formation. 45 Because most patients with TB complete treatment within 1 year, we propose that the effects of TB on the development of PAD may involve the formation of atherosclerotic plaques on vessels affected by chronic inflammation and autoimmunity.
Furthermore, in the majority of patients with active TB, the disease occurred due to the reactivation of latent TB infection (LTBI). Chronic inflammation involving CD4+ and CD8+ T cells, TH17 cells and cytokines such as TNF-α and IFN-γ develops when the immune system restrains tubercle bacilli during LTBI. 46 The similarity of inflammatory cytokines and immune cells in the pathogenesis in LTBI and atherosclerosis may imply that the development of PAD in patients with active TB begins during LTBI. Approximately 2-3 billion people worldwide have LTBI, and 5-15% of them have developed active TB. 47 Studies to investigate the role of LTBI in PAD development may be warranted.
TB increases the risk of PAD
This study had some limitations. First, the insurance data lacked information about the patients' behaviour, such as alcohol abuse and substance use, and other risk factors for PAD, such as smoking, obesity, dietary habits and the current use of medications, including anticoagulant agents and hormone replacement therapy; these variables might have influenced our primary outcomes. Therefore, we adjusted for several smokingrelated co-morbidities, such as COPD, asthma, IHD and stroke, as well as obesity-related diseases, such as DM, hypertension and hyperlipidaemia, to minimize the potential confounding effects. Second, pulmonary images, acid fast staining and culture results were not available; thus, we could not assess the severity of TB or confirm the timing of smear-or culture-negative results in patients with TB. Third, the effects of and treatment periods with different anti-TB medications were not evaluated. Fourth, bias might remain in this retrospective cohort study despite the meticulous adjustment of the model for potential confounders.
In conclusion, patients with TB had a 3.93-fold higher risk of developing PAD than the general population using data from a nationwide population-based database, and this risk became significant after a 1-year follow-up period. We recommend that physicians monitor the development of PAD when caring for patients with TB. 
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